Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTA NASDAQ:GRCE NASDAQ:IPHA NASDAQ:SLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$7.75+1.3%$6.58$4.09▼$17.24$163.53M0.84282,779 shs114,671 shsGRCEGrace Therapeutics$3.04+1.3%$2.92$1.75▼$4.97$41.49M0.9249,431 shs111,749 shsIPHAInnate Pharma$1.75-2.2%$2.05$1.29▼$3.51$165M0.21187,305 shs5,241 shsSLNSilence Therapeutics$5.91+3.1%$5.08$1.97▼$22.47N/A1.39297,817 shs102,744 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals-3.04%+1.19%+2.41%+71.52%-42.87%GRCEGrace Therapeutics-4.15%+1.01%+1.01%+60.43%+299,999,900.00%IPHAInnate Pharma-1.70%-1.38%-16.74%+0.25%-10.05%SLNSilence Therapeutics+3.43%-1.21%+5.33%+149.13%-68.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTAEnanta Pharmaceuticals3.6309 of 5 stars3.42.00.04.70.02.50.0GRCEGrace Therapeutics1.7634 of 5 stars3.50.00.00.00.00.81.3IPHAInnate Pharma2.5234 of 5 stars3.85.00.00.00.01.70.0SLNSilence Therapeutics1.9334 of 5 stars3.43.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals 2.80Moderate Buy$18.00132.26% UpsideGRCEGrace Therapeutics 3.00Buy$12.00294.74% UpsideIPHAInnate Pharma 3.50Strong Buy$11.00528.57% UpsideSLNSilence Therapeutics 2.71Moderate Buy$33.83472.48% UpsideCurrent Analyst Ratings BreakdownLatest GRCE, SLN, ENTA, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025SLNSilence TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.006/13/2025SLNSilence TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.006/3/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $24.005/9/2025SLNSilence TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$4.00 ➝ $3.005/9/2025SLNSilence TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.005/9/2025SLNSilence TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $35.005/2/2025GRCEGrace TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.004/24/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$67.64M2.45N/AN/A$6.08 per share1.27GRCEGrace TherapeuticsN/AN/AN/AN/A$4.86 per shareN/AIPHAInnate Pharma$21.77M7.41N/AN/A$0.11 per share15.91SLNSilence Therapeutics$43.26MN/AN/AN/A$4.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$116.04M-$4.54N/AN/AN/A-149.57%-79.83%-26.65%8/4/2025 (Estimated)GRCEGrace Therapeutics-$9.57M-$0.89N/AN/AN/AN/A-19.45%-16.99%8/8/2025 (Estimated)IPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)SLNSilence Therapeutics-$45.31M-$1.50N/AN/AN/A-260.55%-56.17%-33.96%8/15/2025 (Estimated)Latest GRCE, SLN, ENTA, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q3 2025ENTAEnanta Pharmaceuticals-$1.10N/AN/AN/A$16.21 millionN/A6/20/2025Q4 2025GRCEGrace Therapeutics-$0.23-$0.21+$0.02$0.01N/AN/A5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million5/8/2025Q1 2025SLNSilence Therapeutics-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/ASLNSilence TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A5.295.29GRCEGrace TherapeuticsN/A11.7711.77IPHAInnate Pharma2.522.602.60SLNSilence TherapeuticsN/A8.818.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%GRCEGrace Therapeutics6.08%IPHAInnate Pharma0.16%SLNSilence Therapeutics98.73%Insider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals13.89%GRCEGrace Therapeutics13.51%IPHAInnate Pharma31.89%SLNSilence Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals16021.38 million18.41 millionOptionableGRCEGrace TherapeuticsN/A13.83 million11.96 millionN/AIPHAInnate Pharma22092.18 million62.78 millionNot OptionableSLNSilence Therapeutics100N/AN/ANot OptionableGRCE, SLN, ENTA, and IPHA HeadlinesRecent News About These CompaniesAnalysts Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Target Price at $33.83July 5 at 2:33 AM | americanbankingnews.comSilence Therapeutics (NASDAQ:SLN) Rating Increased to Hold at Wall Street ZenJune 14, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Silence Therapeutics (NASDAQ:SLN)June 13, 2025 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Receives Buy Rating from Chardan CapitalJune 13, 2025 | marketbeat.comSilence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia VeraJune 12, 2025 | businesswire.comWall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a BetJune 6, 2025 | zacks.comWall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to TradeMay 21, 2025 | zacks.comSilence Therapeutics plc GAAP EPS of -C$0.20May 8, 2025 | seekingalpha.comSilence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of DirectorsMay 6, 2025 | finanznachrichten.deSilence Therapeutics Welcomes Tim McInerney to Board of DirectorsMay 6, 2025 | businesswire.comSilence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are BuyingApril 23, 2025 | insidermonkey.comSilence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare ConferenceMarch 5, 2025 | businesswire.comSilence Therapeutics (SLN) Upgraded to Buy: Here's What You Should KnowMarch 4, 2025 | zacks.comSilence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 1, 2025 | uk.finance.yahoo.comSilence Therapeutics plc (SLN) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comSilence Quiets Phase III Pace for Lipoprotein Drug, Seeks PartnerFebruary 28, 2025 | biospace.comBSilence Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateFebruary 27, 2025 | businesswire.comGoldman Sachs Initiates Coverage of Silence Therapeutics plc - Depositary Receipt () (SLN) with Sell RecommendationFebruary 11, 2025 | msn.comSilence Therapeutics hit with new Sell at Goldman Sachs on resource constraintsFebruary 11, 2025 | seekingalpha.comSilence Therapeutics initiated with a Sell at Goldman SachsFebruary 11, 2025 | markets.businessinsider.comGoldman starts Silence Therapeutics at Sell on ‘undifferentiated’ dataFebruary 11, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not Hype3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBy Jeffrey Neal Johnson | June 18, 2025View 3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedSuper Micro Computer Stock's Rally Backed by Strong FinancialsBy Gabriel Osorio-Mazilli | June 19, 2025View Super Micro Computer Stock's Rally Backed by Strong FinancialsRetail Sales Signal Upside for These 3 Consumer StocksBy Gabriel Osorio-Mazilli | June 22, 2025View Retail Sales Signal Upside for These 3 Consumer StocksSnag These 3 Bargain Tech Stocks Before They PopBy Gabriel Osorio-Mazilli | June 27, 2025View Snag These 3 Bargain Tech Stocks Before They PopGRCE, SLN, ENTA, and IPHA Company DescriptionsEnanta Pharmaceuticals NASDAQ:ENTA$7.75 +0.10 (+1.31%) As of 04:00 PM EasternEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Grace Therapeutics NASDAQ:GRCE$3.04 +0.04 (+1.33%) As of 04:00 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Innate Pharma NASDAQ:IPHA$1.75 -0.04 (-2.23%) Closing price 03:29 PM EasternExtended Trading$1.76 +0.00 (+0.29%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Silence Therapeutics NASDAQ:SLN$5.91 +0.18 (+3.14%) Closing price 04:00 PM EasternExtended Trading$5.93 +0.02 (+0.34%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
